Pfizer's New Vaccine Plans Garner Mixed Reactions On Twitter
The news that Pfizer is starting trials on another COVID-19 vaccine that specifically targets the Omicron variant has been met with mixed reactions from the public. Adults ages 18 to 55 are set to take part in the trial which will aim to produce a strong immune response to the contagious strain.
Read More